cv 6504 has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bibby, MC; Hussey, HJ; Tisdale, MJ | 1 |
| Hussey, HJ; Tisdale, MJ | 1 |
2 other study(ies) available for cv 6504 and Adenocarcinoma
| Article | Year |
|---|---|
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC).
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Benzoquinones; Cell Division; Colonic Neoplasms; Growth Inhibitors; Linoleic Acid; Linoleic Acids; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred Strains | 1996 |
Metabolism and pharmacokinetics of the anti-tumour agent 2,3,5-trimethyl-6-(3-pyridylmethyl)1,4-benzoquinone (CV-6504).
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzoquinones; Cell Division; Liver; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Tissue Distribution | 1996 |